225 related articles for article (PubMed ID: 33651454)
1. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.
Suissa K; Schneeweiss S; Kim DW; Patorno E
Diabetes Obes Metab; 2021 Jul; 23(7):1542-1551. PubMed ID: 33651454
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
Levin A; Kaur N; Mainoo NK; Perez A
Clin Ther; 2022 Mar; 44(3):e35-e44. PubMed ID: 35105470
[TBL] [Abstract][Full Text] [Related]
3. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
4. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
Mital S; Nguyen HV
JAMA Netw Open; 2023 Oct; 6(10):e2336400. PubMed ID: 37824146
[TBL] [Abstract][Full Text] [Related]
6. Use of prescription antiobesity drugs in the United States.
Hampp C; Kang EM; Borders-Hemphill V
Pharmacotherapy; 2013 Dec; 33(12):1299-307. PubMed ID: 24019195
[TBL] [Abstract][Full Text] [Related]
7. Obesity Pharmacotherapy.
Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
[TBL] [Abstract][Full Text] [Related]
8. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
Thomas CE; Mauer EA; Shukla AP; Rathi S; Aronne LJ
Obesity (Silver Spring); 2016 Sep; 24(9):1955-61. PubMed ID: 27569120
[TBL] [Abstract][Full Text] [Related]
9. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
Gadde KM; Pritham Raj Y
Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
[TBL] [Abstract][Full Text] [Related]
11. Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
Levi J; Wang J; Venter F; Hill A
Obesity (Silver Spring); 2023 May; 31(5):1270-1279. PubMed ID: 36815242
[TBL] [Abstract][Full Text] [Related]
12. Obesity medications: what does the future look like?
Butsch WS
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):360-6. PubMed ID: 26313898
[TBL] [Abstract][Full Text] [Related]
13. Real-world primary nonadherence to antiobesity medications.
Kan H; Bae JP; Dunn JP; Buysman EK; Gronroos NN; Swindle JP; Bengtson LGS; Ahmad N
J Manag Care Spec Pharm; 2023 Oct; 29(10):1099-1108. PubMed ID: 37594848
[No Abstract] [Full Text] [Related]
14. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
15. The limits and challenges of antiobesity pharmacotherapy.
Gadde KM; Atkins KD
Expert Opin Pharmacother; 2020 Aug; 21(11):1319-1328. PubMed ID: 32292094
[TBL] [Abstract][Full Text] [Related]
16. Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications.
Nguyen B; Clements J
Expert Rev Endocrinol Metab; 2017 Sep; 12(5):303-313. PubMed ID: 30058889
[TBL] [Abstract][Full Text] [Related]
17. Past and present of antiobesity agents: focus on monoamine modulators.
Khorassani FE; Misher A; Garris S
Am J Health Syst Pharm; 2015 May; 72(9):697-706. PubMed ID: 25873617
[TBL] [Abstract][Full Text] [Related]
18. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
[TBL] [Abstract][Full Text] [Related]
19. National trends in antiobesity medication use.
Stafford RS; Radley DC
Arch Intern Med; 2003 May; 163(9):1046-50. PubMed ID: 12742801
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
